RPRX catalysts
Catalysts and events linked to RPRX, newest first.
RPRX stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500M 2026-09-05 · Mixed | capital recovery certainty vs lost upside royalties | Royalty Pharma expects to recoup $500 million investment and earn modest positive return. | Not recorded |
| Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary Endpoint 2026-09-05 · Watch | elimination of future pipeline royalty cash flow upside | Royalty Pharma announced Novartis Phase 3 HORIZON trial failed primary endpoint. | Not recorded |
| Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular Endpoint 2026-09-05 · Mixed | royalty income curtailment mitigated by principal recoupment terms | Royalty Pharma expects to recoup its $500 million investment despite trial miss | Not recorded |
Do these developments change your position?
Review RPRX alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointRPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Trial Fails Primary Cardiovascular EndpointIONS NVS RPRX-11.45%
- 2026-09-05Novartis Pelacarsen Phase 3 Trial Fails; Royalty Pharma Expects to Recoup $500MNVS RPRX
- 2026-09-05Novartis Phase 3 Pelacarsen Cardiovascular Trial Misses Primary EndpointNVS RPRX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.